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Abstract
Background: Viral myocarditis, which is often caused by coxsackievirus B3 (CVB3), is a serious clinical disorder
characterized by excessive myocardial inflammation. Valproic acid (VPA) is described as a histone deacetylase
inhibitor that has anti-inflammatory effects in several inflammatory diseases. However, the role and the detailed
mechanism of VPA in viral myocarditis remain unclear.
Methods: Experimental CVB3-induced myocarditis was induced in mice by intraperitoneally (i.p.) infected with
CVB3. VPA was i.p. administered from day 0 to day 7. The survival, body weight loss, and myocarditis severity of
mice were recorded. Th17 and Treg cells in spleen were analyzed by flow cytometry. Th17/Treg cell-related
cytokine expressions were quantified by ELISA. The effect of VPA on Th17 and Treg cells differentiation was
examined in vitro and in vivo.
Results: Administration of VPA significantly attenuated the clinical severity of myocarditis, and the overall mortality
from CVB3-induced myocarditis. The infiltration of Th17 and Treg cells, as well as the serum level of related
cytokines (IL-17A and IL-10), were increased in CVB3 infected mice. In addition, VPA decreased the percentage of
splenic Th17 cells while increased the percentage of Treg cells. Moreover, VPA downregulated the expression of
IL-17A and upregulated IL-10 in serum and heart tissues of CVB3 infected mice. Additionally, VPA directly inhibited
the differentiation of Th17 cells and promoted both the differentiation and suppressive function of Treg cells in
vitro and in vivo.
Conclusions: Our results suggest that VPA may thus be a promising strategy in the therapy of viral myocarditis.
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Background
Viral myocarditis, which is often caused by coxsackie-
virus B3 (CVB3)-triggered myocarditis, is one of the
leading causes of severe heart failure, and even sudden
death in young adults [1]. Viral myocarditis is an
immune-mediated disease characterized by inflamma-
tory infiltration of the myocardium and cardiac myocyte
necrosis [2, 3]. It has been shown that several T helper
(Th) subsets, such as Th17 and Treg cells, are involved
in the pathogenesis of viral myocarditis [4–6]. Th17 cells
are a new subset of CD4+ T cells that secrete the charac-
teristic cytokine interleukin-17A (IL-17A). There is also
evidence that Th17 cells contribute to myocarditis
development and pathogenesis [4, 5, 7]. Treg cells char-
acteristically express the transcription factor forkhead
box P3 (Foxp3), secrete anti-inflammatory cytokines
such as IL-10 and transforming growth factor-β (TGF-β),
and act to maintain immune homeostasis and control
immune-mediated tissue injury. Treg cells are also
involved in inflammation and tissue destruction during
viral myocarditis [4, 6]. More importantly, Th17 and Treg
cells are subsets of the CD4+ T cell which are vital modu-
lators of the innate and adaptive immune response in
many immune diseases [8]. A Th17/Treg imbalance has
been found in many diseases, including viral myocarditis
[4, 9]. However, the expression and function of Th17 and
Treg cells in viral myocarditis remain unclear.
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Histone deacetylases (HDACs) are part of a vast
family of enzymes involved in chromatin remodeling
that play a key role in the differentiation and immune
function of T cells [10, 11]. Inhibition of HDAC activ-
ity is initially recognized as a powerful anti-cancer
therapeutic strategy and is recently found to be impli-
cated in the regulation of the neurodegenerative
diseases, and inflammatory diseases [12]. Valproic acid
(VPA), a short-chain branched fatty acid, is a clinic-
ally approved HDAC inhibitor that is traditionally
used in the treatment of epilepsy and has been shown
to be a safe, effective treatment in humans [13].
Accumulated experimental and clinical data also show
that VPA could be a potent anticancer drug, and has neu-
roprotective, axonal remodeling and anti-inflammatory
effects. Lv et al. reported that VPA could inhibit experi-
mental autoimmune encephalomyelitis in mouse model
by inducing apoptosis in activated T cells and maintaining
the immune homeostasis [14]. Administration of VPA
could decrease disease incidence and severity in collagen
induced mouse arthritis through effects on the production
and function of Treg cells [15]. VPA could also suppress
proinflammatory cytokine synthesis and reduce the
severity of dextran sodium sulfate-induced colitis [16].
Thus, it is reasonable to hypothesize that HDAC in-
hibitor plays a protective role in viral myocarditis.
One study showed that HDAC inhibitors could
suppress CVB3 growth in vitro and CVB3-induced
myocardial injury in vivo [17]. However, the role and
the detailed mechanism of VPA in viral myocarditis
remain unclear. In the current study, we observed
that administration of VPA ameliorated CVB3-
induced viral myocarditis by modulating Th17/Treg
imbalance. Our findings suggest that VPA may be a




Six to eight week old male specific pathogen-free BALB/
c mice were purchased from Vital River Laboratories
(Beijing, China) and maintained at the Animal Center of
the Nankai University (Tianjin, China). CVB3 (Nancy
strain) was propagated in HeLa cells. The viral titer was
determined using a 50 % tissue culture infectious dose
(TCID50) assay on HeLa cell monolayers and calculated
by the Reed-Muench method. This study was carried
out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The experimental
protocol was approved by the Committee on the Ethics
of Animal Experiments of the Nankai University (Permit
Number: 15–1567).
CVB3 infection and drug administration
BALB/c mice were infected with an intraperitoneal (i.p.)
injection of 0.1 mL of phosphate-buffered saline (PBS)
containing 103 TCID50 of the virus on day 0. Mice
administered i.p. with PBS were taken as mock control.
Mice were administered VPA (250 mg/kg; Selleck) or
vehicle solution (PBS) by i.p. injection daily from day 0
to day 7.
Histopathology and myocarditis scoring
Mice hearts were fixed in 10 % formalin, paraffin em-
bedded, and stained with hematoxylin and eosin (H&E).
Severity scores of myocarditis were graded by two
independent pathologists in a double-blinded manner
based on the following semi-quantitative scale: 0 = no
inflammation; 1 = one to five distinct mononuclear
inflammatory foci, with the involvement of 5 % or less of
the cross-sectional area; 2 = more than five distinct
mononuclear inflammatory foci, or the involvement of
over 5 % but not over 20 % of the cross-sectional
area; 3 = diffuse mononuclear inflammation involving
over 20 % of the area, without necrosis; and 4 = diffuse
inflammation with necrosis.
Flow cytometry
Single-cell suspensions were obtained from spleen of
mice on indicated days postinfection. For intracellular
cytokine staining, cells were stimulated for 5–6 h with
PMA (50 ng/mL) and ionomycin (500 ng/mL) in the
presence of brefeldin A (10 μg/ml). Cells were harvested,
washed, and stained with surface molecule antibodies in
the presence of FcR-Block (BD Bioscience). After the
wash, cells were then fixed using CytoFix/CytoPerm
buffer (BD Bioscience) and stained with antibodies
against intracellular cytokines or isotype control on ice
for 30 min. The following Abs were used for staining:
FITC-conjugated anti-mouse CD3, PE-conjugated anti-
mouse IL-17A, PE-Cy5.5-conjugated anti-mouse IFN-γ,
and APC-conjugated anti-mouse CD4 (BD Bioscience).
Treg cell staining was performed using a Treg staining
kit according to the manufacturer’s instructions
(eBioscience). Data were acquired on a FACS Calibur
(BD Bioscience) and analyzed using Flowjo software
(TreeStar).
Real-time PCR
Total RNA from heart tissues was extracted with TRIzol
Rreagent (Invitrogen), and reverse transcripted into
cDNA. Transcription levels of Il17a and Il10 genes were
analyzed by real-time quantitative PCR using an ABI
7500 (Applied Biosystems) and SYBR green system
(TaKaRa) by following the manufacturer’s protocol. The
primers used were: Il-17a, forward: 5’-CTCCAGAAGG
CCCTCAGACTAC-3’ and reverse: 5’-AGCTTTCCCTCC
Jin and Guo Virology Journal  (2016) 13:168 Page 2 of 9
GCATTGACACAG-3’; Il10, forward: 5’- GACAAC
ATACTGCTAACCGACTC-3’ and reverse: 5’- GACAAC
ATACTGCTAACCGACTC-3’; CVB3, forward: 5’- GCAC
ACACCCTCAAACCAGA -3’ and reverse: 5’- ATGAAA
CACGGACACCCAAAG -3’; GAPDH, forward: CTCT
GGAAAGCTGTGGCGTGATG-3’ and reverse: 5’- ATG
CCAGTGAGCTTCCCGTTCAG-3’. The relative gene
expressions were normalized to the level of GAPDH and
quantified by the 2-△△CT method. All reactions were
performed in at least duplicate for each sample.
Western blotting
About 20 μg of total protein form heart tissues was
extracted from CVB3 infected mice, and separated by
10 % SDS-PAGE, transferred onto polyvinylidene fluor-
ide membranes. Membranes were blocked with nonfat
dry milk solution (5 % in Tris-buffered saline) containing
0.1 % Tween 20 for 1 h, and then incubated with mouse
anti-Enterovirus VP1 antibody (clone 5-D8/1, Dako,
Hamburg, Germany) overnight at 4 °C. After being
washed with PBS containing 0.1 % Tween 20, the mem-
branes were incubated with Horseradish peroxidase
(HRP)-conjugated goat anti-mouse antibody for 1 h at
room temperature. The bands were visualized by en-
hanced chemiluminescence (Beyotime, Shanghai, China)
and detected by an Alpha Imager (Alpha Innotech, San
Leandro, CA, USA).
ELISA
Levels of IL-17A and IL-10 in serum or cell culture su-
pernatants were determined by ELISA kits (eBioscience)
according to the manufacturer’s instructions. All samples
were measured in triplicate.
In vitro T cells differentiation
Naive CD4+T cells from normal BALB/c mice were puri-
fied using CD4+ naive T cell isolation kit (STEMCELL
Technologies) according to the manufacturer’s instruc-
tion. Purified cells were activated by plate-coating
anti-CD3 (10 μg/ml; BD Pharmingen) plus anti-CD28
(2 μg/ml; BD Pharmingen) for 5 days under the follow-
ing polarizing conditions: TGF-β (3 ng/ml, Peprotech),
IL-6 (30 ng/ml; eBioscience), IL-23 (20 ng/ml; R&D),
anti-IFN-γ (10 μg/ml, BD Pharmingen), anti-IL-4
(10 μg/ml, BD Pharmingen) for Th17 polarization,
and TGF-β1 (5 ng/ml, Peprotech), anti-IFN-γ (10 μg/ml,
BD Pharmingen), anti-IL-4 (10 μg/ml, BD Pharmingen)
for Treg polarization. VPA or vehicle solution was added
on day 0.
In vitro suppression assay
CD4+CD25+ T cells were isolated from the spleen of
CVB3 infected mice treated with VPA or vehicle on day
6 using Mouse CD4+CD25+ Regulatory T Cell Isolation
Kit (STEMCELL Technologies). CD4+CD25− T cells
were used as T effector (Teff ) cells and labeled with
1 μM CFSE (Life technologies). Purified Treg cells (5 ×
104 cells) were cultured with Teff cells at 1:2 ratios in
96-well round bottom plates coating with anti-CD3
(10 μg/ml; BD Pharmingen) plus anti-CD28 (2 μg/ml;
BD Pharmingen). Ninety-six hour later, the suppression
was assayed by FACS analysis for dilution of CFSE in
gated Teff cells. Data were acquired on a FACS Calibur
(BD Bioscience) and analyzed using Flowjo software
(TreeStar).
Statistical analysis
All Data were presented as means ± SEM. Differences
between experimental groups were analyzed using an
unpaired Student’s t-test. Survival was estimated by the
Kaplan-Meier method and compared by the log-rank
test. All data were analyzed with GraphPad Prism
version 5.0 (GraphPad Software Inc.). P < 0.05 was
considered significant difference.
Results
VPA treatment attenuates CVB3-induced myocarditis
in mice
To investigate the effect of VPA on CVB3-induced viral
myocarditis, mice were first infected with CVB3 or mock
and then treated daily with either VPA (i.p., 250 mg/kg)
or vehicle from day 0 to day 7 after infection. As
expected, mice receiving PBS alone developed no sign of
viral myocarditis, whereas the signs of viral myocarditis
were apparent in CVB3-infected mice, including weak-
ness, irritability, lethargy and weight loss, with 40 % of
mice died on day 14 postinfection (Fig. 1a). In contrast,
the administration of VPA significantly ameliorated
CVB3-induced myocarditis in CVB3-infected mice,
with ~ 80 % of them surviving without severe viral
myocarditis (P = 0.02, Fig. 1a). This was accompanied by
less body weight loss (Fig. 1b). The pathological myocardi-
tis score also was lower in VPA treated CVB3-infected
mice (Fig. 1c and d). However, administration of VPA to
mock-infected mice caused no mortality, bodyweight loss,
and cardiac pathological analysis showed no evidence of
viral myocarditis (Fig. 1a–d). Taken together, VPA
treatment attenuates CVB3-induced myocarditis in mice
without s systemic toxicity.
VPA administration regulates the proportion of Th17 and
Treg cells
Increasing evidence has demonstrated that a balance be-
tween proinflammatory Th17 and anti-inflammatory
Treg cells is essential to maintain immune tolerance
and prevent the onset of several inflammatory and
autoimmune diseases [8]. Therefore, to understand
the mechanism by which VPA treatment reduced
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CVB3-inducedmyocarditis, we first monitored the kin-
etics of T cell proportion during CVB3 infection. As
shown in Fig. 2a and b, in the CVB3-infected mice,
CD4+IL-17+ Th17 cells derived from spleen signifi-
cantly increased since the early stage after CVB3
infection compared with the mock-infected mice. In
addition, the percentages of CD4+CD25+Foxp3+Treg
cells in CVB3 infected mice were also higher than
those in the mock control mice (Fig. 2c and d).
Moreover, the characteristic cytokines produced by
Th17 (IL-17A) and Treg (IL-10) cells were elevated in
serum from CVB3 infected mice (Fig. 2e and f ).
These data suggest that Th17 and Treg cells are
involved in CVB3-induced myocarditis.
We then treated CVB3 infected mice with VPA or ve-
hicle and analyzed the proportion of Th17 and Treg cells
from spleen on the indicated days after CVB3 infection.
Flow cytometry analysis showed that, compared with
vehicle control, VPA treatment markedly reduced the
frequencies of splenic Th17 cells (Fig. 3a and b), whereas
increased the frequencies of Treg cells in the spleen on
day 3, 6 and 12 (Fig. 3c and d). We also detected sub-
stantially lower serum levels of Th17-related cytokines
(IL-17A) and higher serum levels of Treg-related
cytokines (IL-10) in VPA treated mice during CVB3
infection (Fig. 3e and f). Additionally, the mRNA expres-
sions of cardiac IL-17A in VPA mice were markedly
reduced compared to the vehicle control mice (Fig. 3g);
whereas the mRNA levels of cardiac IL-10 in the VPA
mice were apparently elevated compared to the vehicle
control mice (Fig. 3h). We also examined the effect of
VPA on CVB3 viral replication in vivo, the results
showed that VPA significantly reduced virus replication
(Fig. 3i) and viral protein VP1 expression (Fig. 3j) in
heart tissues of VPA treated mice during CVB3 infection.
Taken together, our data suggest that the decrease in
Th17 cells and increase in Treg cells, as well as decreased
CVB3 viral replication may be the major causes of VPA-
mediated viral myocarditis inhibition.
VPA influences Th17 and Treg cells differentiation in vitro
and in vivo
VPA is known to directly inhibit class I and II HDAC
activity and cause a hyperacetylation of histones. Since
histone acetylation pattern remodeling has been found
to associate with T cell differentiation and cytokines
expression [18], we proposed that VPA may influence
Th17 and Treg cells differentiation directly. Firstly, puri-
fied naive CD4+ T cells from normal BALB/c mice were
cultured under Th17 or Treg cells-polarizing conditions
with or without VPA. As shown in Fig. 4a–d, VPA inhib-
ited the in vitro differentiation of Th17 cells, whereas
promoted Treg cells differentiation in a dose depend
manner.
We next examined whether VPA directly influences
the immune function of in vivo-differentiated Th17 and
Fig. 1 Administration of VPA attenuates CVB3-induced myocarditis in mice. Male BALB/c mice (n = 20 per group) were infected with PBS or CVB3
on day 0, and then treated with either VPA (i.p., 250 mg/kg) or vehicle (PBS) daily from day 0 to day 7 postinfection. The survival rate (a) and body
weight change (b) were monitored daily until day 14. Paraffin sections of heart tissues were prepared on day 0, 3, 6, 9, 12 postinfection and cardiac
injury was revealed by H&E. Representative H&E on day 6 postinfection was shown (c). The myocarditis pathological score was determined by analysis
of the H&E-stained sections (d). Results are presented as the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, compared
with CVB3 group
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Treg cells. Spleen CD4+ T cells were isolated from mice
6d after CVB3 infection and cultured with or without
VPA for 24 h to determine cytokine production. Data
showed that VPA reduced IL-17A and induced IL-10
production in a dose-dependent manner (Fig. 4e and f).
Furthermore, we assessed the effect of VPA on immune
function of Treg cells. CD4+ CD25+ T cells from CVB3
infected mice treated with VPA or vehicle were isolated
and co-cultured with CFSE-labeled CD4+CD25−T ef-
fector cells from naïve mice on anti-CD3/CD28 mAb
coated plates. As shown in Fig. 4g and h, the percentage
of proliferative Teff cells was reduced from 74.6 % (in
the absence of Treg) to 58.4 % by the addition of Treg
from vehicle-treated mice. However, in the presence of
VPA-treated Treg, the population of proliferating Teff
cells was further reduced to 39.2 %, indicating an en-
hanced Treg suppressive function in CVB3 infected mice
following VPA treatment. Altogether, these data suggest
that VPA directly inhibits the differentiation of Th17
cells and promotes both the differentiation and suppres-
sive function of Treg cells in vitro and in vivo.
Discussion
In this study, we provided the first evidence that admin-
istration of VPA protected against CVB3 induced viral
myocarditis. We also observed an imbalance of Th17/
Treg cells during the CVB3 infection. The infiltration of
Th17 and Treg cells, as well as the serum level of related
cytokines, also was increased in CVB3 infected mice. In
addition, the protective effects of VPA against viral
myocarditis were closely associated with Th17/Treg
imbalance modulation and decreased CVB3 viral replica-
tion during the pathogenesis of viral myocarditis. VPA
directly inhibited the differentiation of Th17 cells and
Fig. 2 Th17 and Treg cells are involved in CVB3-induced myocarditis. Male BALB/c mice (n = 20 per group) were infected with PBS or CVB3 on day 0.
The frequencies of CD4+IL-17+ Th17 cells or CD4+CD25+Foxp3+ Treg cells in mice from spleen on indicated days postinfection were analyzed by Flow
cytometry (a and c, left panels). Bar graphs showed the representative percentages of Th17 cells or Treg cells (b and d, right panel). The serum levels of
characteristic cytokines IL-17A (e) and IL-10 (f) in CVB3 infection mice were determined by ELISA. Results are presented as the mean ± SEM of three
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, compared with PBS group
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promoted both the differentiation and suppressive func-
tion of Treg cells in vitro and in vivo, thus possibly pro-
viding a protective effect against viral myocarditis.
Therefore, our results suggest that VPA may thus be a
promising strategy to prevent or treat viral myocarditis.
Many studies reported that Th17/Treg functional
imbalance exists during acute CVB3-induced myocardi-
tis, Treg and proinflammatory Th17 cells have been
suggested to play either suppressor or effector roles,
respectively. Xie et al. showed that acute myocarditis
(See figure on previous page.)
Fig. 3 Administration of VPA regulates the proportion of Th17 and Treg cells. Male BALB/c mice (n = 20 per group) were infected with CVB3 on
day 0, and then treated with either VPA (i.p., 250 mg/kg) or vehicle (PBS) daily from day 0 to day 7 postinfection. The frequencies of Th17 cells or
Treg cells in mice from spleen on indicated days postinfection were analyzed by Flow cytometry (a and c, left panels). Bar graphs showed the
representative percentages of Th17 cells or Treg cells (b and d, right panel). The serum levels of characteristic cytokines IL-17A (e) and IL-10 (f) in
CVB3 infection mice were determined by ELISA. mRNA expression of IL-17A (g) and IL-10 (h) in cardiac tissues were detected by qRT-PCR on indi-
cated days postinfection. i The CVB3 replication in cardiac tissues were detected by qRT-PCR on indicated days postinfection. j The expression of
viral capsid protein (VP1) in cardiac tissues was detected by western blot on indicated days postinfection. Results are presented as the mean ± SEM of
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, compared with CVB3 group
Fig. 4 VPA influences Th17 and Treg cells differentiation in vitro and in vivo. Purified naive CD4+ T cells from normal BALB/c mice were cultured
with different concentrations of VPA under Th17 or Treg cells-polarizing conditions. The differentiations of Th17 cells or Treg cells were analyzed
by Flow cytometry (a and c, left panels). Bar graph shows the representative percentage of in vitro-differentiated Th17 cells or Treg cells (b and d,
right panel). Spleen CD4+ T cells isolated from mice 6d after CVB3 infection were treated with PBS or VPA for 24 h ex vivo, the supernatants were
collected and ELISA was performed to determine the level of IL-17A (e) and IL-10 (f). CD4+CD25+ T cells isolated from CVB3 infected mice treated
with VPA or vehicle were isolated on day 6 and co-cultured with CFSE-labeled CD4+CD25−T effector (Teff) cells from naïve mice on anti-CD3/
CD28 mAb coated plates. The suppression was assayed by Flow cytometry for dilution of CFSE in gated Teff cells (g and h). Results are presented
as the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001
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exhibited apparent increases in Th17 cells and Th17-
related cytokines (IL-17A, IL-21). Meanwhile, marked
increases in Treg cells and Treg-related cytokines (TGF-
β, IL-10 and IL-6) also were observed in myocarditis
mice [4]. They further demonstrated that blockade of
IL-17A protected against CVB3-induced myocarditis by
increasing COX-2/PGE2 production in the heart [7]. On
the other hand, Cao et al. found that adoptive transfer of
Treg cells protected against CVB3-induced cardiac fibro-
sis [6]. Consistent with these studies, in the present
study, we also found an increased percentage of Th17
cells and Treg cells in CVB3 infected mice from early
stage of infection, suggesting that Th17 and Treg cells
are involved in CVB3-induced myocarditis. Thus,
personalized medicine that alters the balance between
Treg and Th17 cells may ameliorate viral pathology
during CVB3 infections.
VPA is known to interfere with multiple regulatory
mechanisms, including class I and II HDACs, Akt, ERK,
and NF-κB pathway [19, 20]. Recently, VPA has been
found to have anti-inflammatory effects that are prob-
ably associated with its HDAC inhibitory activity [21].
Histone acetylation remodeling has been found to
associate with T cell differentiation and expression of a
variety of cytokines [18]. HDAC inhibitors effectively
reduced the expression of pro-inflammatory cytokines,
including IL-1β, IFN-γ, TNF-α, and IL-6 [11]. Therefore,
VPA may function through the HDAC inhibitory activity
to attenuate inflammation in viral myocarditis. In
addition, Shim et al. reported that Histone deacetylase
inhibitors Trichostatin A could suppress CVB3 replica-
tion in Hela cells in vitro, and subsequently reduces
CVB3 titers in the heart and protects mice from myocar-
ditis [17]. In our study, we also observed significantly
decreased CVB3 replication in heart tissues in vivo,
suggesting that decreased viral replication is also neces-
sary for VPA-mediated amelioration of viral myocarditis.
More importantly, administration of VPA ameliorated
viral myocarditis accompanied by a marked reduction in
the frequency of Th17 cells and relative cytokines, VPA
can directly inhibit the in vitro and in vivo differenti-
ation of Th17 cells. In addition, Foxp3 has an essential
role in the development and function of natural and
induced Treg and as such represents a key target to
modulate Treg functions. Acetylation of Foxp3 is linked
to stability of Foxp3 that can be regulated by HAT (i.e.
CBP/p300 and TIP60) and HDAC (i.e. HDAC7, HDAC9
and SIRT1) [22, 23]. For example, in vivo treatment with
VPA increases the number and function of Treg cells
and reduces disease severity in the collagen induced
mouse arthritis [15]. In humans, HDAC inhibition
(vorinostat) regulates inflammation and enhances Tregs
after allogeneic hematopoietic cell transplantation through
increased STAT 3 acetylation and induced indoleamine-
2,3-dioxygenase [24]. In our study, VPA treatment in-
creased the percentage of Treg cells in CVB3 infected
mice, and promoted both the differentiation and suppres-
sive function of Treg cells in vitro and in vivo. Thus,
modulation of Th17/Treg cell differentiation and immune
function may represent a mechanism by which VPA
controls viral myocarditis.
Conclusions
In summary, we have studied the effect of VPA in CVB3
induced myocarditis, an animal model of human viral
myocarditis. Our data demonstrate that VPA treatment
greatly reduced the severity and duration of viral
myocarditis and attenuated inflammation in the heart.
Furthermore, VPA treatment in viral myocarditis sup-
pressed the polarization of Th17 cells but induced the
Treg cells. Therefore, our investigation showed that VPA
could effectively ameliorate viral myocarditis through
modulating Th17/Treg imbalance, suggesting that VPA
may be an option in the therapy of viral myocarditis.
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